Institutional shares held 125 Million
4.6M calls
2.43M puts
Total value of holdings $5.7B
$210M calls
$111M puts
Market Cap $4.31B
94,144,096 Shares Out.
Institutional ownership 132.27%
# of Institutions 407


Latest Institutional Activity in CYTK

Top Purchases

Q4 2024
Fny Investment Advisers, LLC Shares Held: 14.5K ($665K)
Q4 2024
Harbor Capital Advisors, Inc. Shares Held: 45.1K ($2.06M)
Q4 2024
Mirador Capital Partners LP Shares Held: 65.6K ($3M)
Q4 2024
Inspire Investing, LLC Shares Held: 8.5K ($389K)
Q4 2024
Skopos Labs, Inc. Shares Held: 44 ($2.01K)

Top Sells

Q4 2024
Oak Ridge Investments LLC Shares Held: 14.9K ($680K)
Q4 2024
Nisa Investment Advisors, LLC Shares Held: 14.7K ($672K)
Q4 2024
Gamma Investing LLC Shares Held: 294 ($13.4K)
Q4 2024
Nelson, Van Denburg & Campbell Wealth Management Group, LLC Shares Held: 3.72K ($170K)
Q4 2024
Fifth Third Bancorp Shares Held: 690 ($31.6K)

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.


Insider Transactions at CYTK

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
597K Shares
From 19 Insiders
Grant, award, or other acquisition 267K shares
Exercise of conversion of derivative security 330K shares
Sell / Disposition
533K Shares
From 15 Insiders
Open market or private sale 450K shares
Payment of exercise price or tax liability 80.8K shares
Bona fide gift 2.11K shares

Track Institutional and Insider Activities on CYTK

Follow CYTOKINETICS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK